Vaccines Research Update – 20 Mar 2026: Arexvy FDA Expansion, ETVAX Data and More

Respiratory Research Update – 20 Mar 2026: MOLBREEVI FDA Progress, Tyvaso Phase 3 Data and More

Gene and Cell Therapy Update – 19 Mar 2026: ST-920 BLA Progress, Deramiocel PDUFA and More

Women’s Health Update – 18 Mar 2026: Enhertu Priority Review, Roche Phase III and More

Neuroscience Update – 18 Mar 2026: Phase 3 HARMONIA in DM1, Roche ApoE4 CE Mark and More

Obesity Update – 17 Mar 2026: China Approves Ecnoglutide, ASC30 Phase II Data and More

Oncology Update – 16 Mar 2026: ENHERTU Priority Review and Zynyz EU Approval and More

Public Health Update – 13 Mar 2026: Gene Therapy Breakthrough, Antibiotic Pipeline Concerns and More

Rare Diseases Update – 12 Mar 2026: ST-920 BLA Progress, JUXTAPID Pediatric Approval and More

Cardiovascular Update – 12 Mar 2026: Abbott CardioMEMS HERO FDA Clearance, Relief Implant and More

ARTIFICIAL INTELLIGENCE and DIGITAL HEALTH Update – 11 Mar 2026: ChatGPT Health safety study & more

Immunology Update – 11 March 2026: Sotyktu PsA Approval, Dupixent AFRS Approval and More

Endocrinology Update – 10 Mar 2026: Sogroya Pediatric Approval, Desmoda FDA Approval and More

Hematology Update – 09 Mar 2026: TECVAYLI + DARZALEX FDA Approval, Rusfertide Priority Review & More

Vaccines Update – 06 March 2026: Moderna mRNA-1073, mCombriax and More

Respiratory Research Update – 06 March 2026: MOLBREEVI BLA Priority Review, AATD Gene Editing & More

Gene and Cell Therapy Update – 5 March 2026: FDA Bespoke Pathway, DTX401 Priority Review and More

Women’s Health Update – 04 Mar 2026: Roche NDA Accepted, Iza-bren Phase 3 Win and More

Neuroscience Update – 04 Mar 2026: Tirabrutinib, TEV-’749 NDAs Accepted and More

Obesity Update – 3 March 2026: Taltz + Zepbound, UBT251 19.7% Loss and More

Oncology Update – 02 Mar 2026: FDA Full Approval for BRAFTOVI, FDA Accepts Giredestrant NDA and More

AAAAI 2026 Preview by LucidQuest

ESGO 2026 Preview by LucidQuest

Public Health Update – 27 Feb 2026: AI triage tool, Stanford immune reset cures T1D and more

Rare Diseases Update – 26 Feb 2026: NICE backs ARG1 therapy, FDA bespoke pathway and More

Cardiovascular Update – 26 Feb 2026: FDA OK's ENHANCE Trial, Symplicity Spyral Approval and More

Immunology Update – 25 Feb 2026: Phase 3 kidney disease win, FDA BLA filing in autoimmune PAP & More

Endocrinology Update – 24 Feb 2026: NICE Type 2 First-Line Shift, Portal Pump Breakthrough and More

Hematology Update – 23 Feb 2026: AstraZeneca Calquence US OK, BMS Iberdomide NDA and More

ECCO 2026 Preview by LucidQuest

Vaccines Research Update – 20 Feb 2026: Delonix MenB Vaccine, Moderna Patent Setback and More

Respiratory Research Update – 20 Feb 2026: Pulmovant’s Phase 2 Enrollment, Breztri Results and More

Gene & Cell Therapy Update – 19 Feb 2026: FDA Rejects RGX-121, Orna Therapeutics Acquisition & More

Women’s Health Update – 18 Feb 2026: KEYTRUDA Approval for Ovarian Cancer, Migraine Trial and More

Neuroscience Update – 18 Feb 2026: Teva’s Pediatric Migraine Approval, Kite’s Yescarta Update & More

Obesity Update – 17 Feb 2026: CagriSema Tops Ozempic, Pfizer’s Weight Loss Breakthrough and More

Oncology Update–16 Feb 2026: KEYTRUDA FDA Ovarian Approval, Imfinzi EU CHMP Backing and More

Public Health Update – 13 February 2026: 37% of Cancers Preventable, LDL Cut 60% and More

Rare Disease Update – 12 February 2026: Venglustat GD3 win, RGX-121 CRL and More

Cardiovascular Update – 12 Feb 2026: OCEANIC-STROKE results, new AIS guideline and more

H2 2025 Health Mobile Apps Landscape

Immunology Update – 11 Feb 2026: EU Gastric Periop IO, China UC S1P and More

Endocrinology Update – 10 Feb 2026: China OKs Xianyida, CagriSema Tops Ozempic and More

ARTIFICIAL INTELLIGENCE and DIGITAL HEALTH Update – Feb 9, 2026: CardioMEMS, Samsung Health & More

Hematology Update – 09 Feb 2026: D-VRd FDA OK, HYMPAVZI Priority Review and More

Respiratory Update – 06 Feb 2026: China OKs Trelegy for Asthma, Ensifentrine NDA and More

Vaccines Research Update – 06 Feb 2026: EU Approves Arexvy 18+, Brazil IXCHIQ Pilot and More

Gene & Cell Therapy Update – 5 Feb 2026: CAR-T Breakthrough Designation, Glioblastoma CAR-NK & More

Womens Health Update – 4 Feb 2026: FDA Review for TNBC Treatment, OTC Contraceptive in Japan & More

Neuroscience Update – 4 Feb 2026: Ph 2 Study in Tardive Dyskinesia, Ph 3 Results for Gaucher & More

Obesity Update – 03 Feb 2026: CT-388 Phase 2 Data, Monthly Portfolio Deal and More

Oncology Update – 02 Feb 2026: ENHERTU China 2L Gastric Approval, AKEEGA CHMP Opinion and More

Public Health Update – Jan 29, 2026: Breast Cancer Blood Test, Exercise Benefits, BPA Risks and More

Cardiovascular Update – 29 Jan 2026: Canada OKs Oral GLP-1 for CV Risk, Evolocumab Cuts MACE & More

Rare Diseases Update – 29 Jan 2026: EU approves C3G treatment, FDA Orphan Designation for MF & More

Immunology Update – 28 Jan 2026: Novartis’ ianalumab Breakthrough, Sobi’s Aspaveli Approval and More

Endocrinology Update – 27 January, 2026: EU OKs T1D delay therapy, US denosumab biosimilars and more

ARTIFICIAL INTELLIGENCE and DIGITAL HEALTH Update – January 26, 2026: ARPA-H Cardio Agents and More

Hematology Update – 26 Januray, 2026: Epcoritamab PFS in DLBCL, FDA MRD/CR Draft and More

Respiratory Update – 23 January, 2026: Krystal Biotech CFTR, Kinaset’s $103M for Asthma and more